Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE DATED MARCH 3, 2015 - QUANTRX BIOMEDICAL CORP | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 3, 2015
|
Commission File Number: 000-17119
|
QuantRx Biomedical Corporation
|
(Exact name of small business issuer as specified in its charter)
Nevada
(State or other jurisdiction of incorporation or organization)
|
330202574
(IRS Employer Identification No.)
|
10190 SW 90th Avenue, No. 4690, Tualatin, Oregon 97123
|
(Address of principal executive offices)
503-575-9385
|
(Registrant's Telephone number)
Not Applicable
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other Events.
On March 3, 2015, QuantRx Biomedical Corporation (the "Company") issued a press release providing an update on the technological progress of its genomic diagnostics platforms. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
See Exhibit Index
SIGNATURES
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 4, 2015
|
QuantRx Biomedical Corporation
By: /s/ Dr. Shalom Hirschman
|
Name: Dr. Shalom Hirschman
|
|
Title: Chief Executive Officer
|
Exhibit Index
|
|
|||
Exhibit No.
|
Description
|
|||
EX-99.1
|
|
Press Release dated March 3, 2015.
|